Risk of clinical events by the status of hs-CRP levels and infarction numbers in patients with minor ischaemic stroke or TIA at 1-year follow-up
| Outcome | Group | No | Events at 1 year, n (%) | Model 1* | Model 1† | ||
| Adjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P Value | ||||
| Ischaemic stroke | Non-elevated hs-CRP levels with NAI | 142 | 5 (3.5) | Ref | Ref | ||
| Non-elevated hs-CRP levels with SAI | 273 | 28 (10.3) | 3.18 (1.23 to 8.24) | 0.02 | 3.23 (1.12 to 9.29) | 0.03 | |
| Non-elevated hs-CRP levels with MAIs | 113 | 16 (14.2) | 4.41 (1.61 to 12.04) | 0.004 | 3.93 (1.31 to 11.73) | 0.01 | |
| Elevated hs-CRP levels with NAI | 54 | 3 (5.6) | 1.62 (0.39 to 6.78) | 0.51 | 1.69 (0.40 to 7.22) | 0.48 | |
| Elevated hs-CRP levels with SAI | 141 | 18 (12.8) | 3.92 (1.45 to 10.57) | 0.007 | 3.33 (1.10 to 10.12) | 0.03 | |
| Elevated hs-CRP levels with MAIs | 84 | 14 (16.7) | 5.32 (1.91 to 14.83) | 0.001 | 4.68 (1.54 to 14.23) | 0.007 | |
| Composite events ‡ | Non-elevated hs-CRP levels with NAI | 142 | 5 (3.5) | Ref | Ref | ||
| Non-elevated hs-CRP levels with SAI | 273 | 28 (10.3) | 3.17 (1.22 to 8.22) | 0.02 | 3.29 (1.16 to 9.37) | 0.03 | |
| Non-elevated hs-CRP levels with MAIs | 113 | 18 (15.9) | 4.95 (1.84 to 13.34) | 0.002 | 4.62 (1.58 to 13.48) | 0.005 | |
| Elevated hs-CRP levels with NAI | 54 | 4 (7.4) | 2.16 (0.58 to 8.04) | 0.25 | 2.29 (0.60 to 8.70) | 0.22 | |
| Elevated hs-CRP levels with SAI | 141 | 18 (12.8) | 3.90 (1.45 to 10.52) | 0.007 | 3.44 (1.15 to 10.34) | 0.03 | |
| Elevated hs-CRP levels with MAIs | 84 | 16 (19.0) | 6.07 (2.21 to 16.63) | <0.001 | 5.48 (1.85 to 16.24) | 0.002 | |
| TIA | Non-elevated hs-CRP levels with NAI | 142 | 10 (7.0) | Ref | Ref | ||
| Non-elevated hs-CRP levels with SAI | 273 | 2 (0.7) | 0.10 (0.02 to 0.46) | 0.003 | 0.14 (0.03 to 0.70) | 0.02 | |
| Non-elevated hs-CRP levels with MAIs | 113 | 3 (2.7) | 0.38 (0.10 to 1.38) | 0.14 | 0.50 (0.12 to 2.09) | 0.34 | |
| Elevated hs-CRP levels with NAI | 54 | 4 (7.4) | 1.16 (0.36 to 3.73) | 0.80 | 1.04 (0.30 to 3.56) | 0.95 | |
| Elevated hs-CRP levels with SAI | 141 | 2 (1.4) | 0.21 (0.05 to 0.95) | 0.04 | 0.29 (0.05 to 1.52) | 0.14 | |
| Elevated hs-CRP levels with MAIs | 84 | 4 (4.8) | 0.73 (0.23 to 2.36) | 0.60 | 0.95 (0.23 to 3.89) | 0.95 | |
| Any bleeding | Non-elevated hs-CRP levels with NAI | 142 | 3 (2.1) | Ref | Ref | ||
| Non-elevated hs-CRP levels with SAI | 273 | 7 (2.6) | 1.33 (0.34 to 5.15) | 0.68 | 2.15 (0.43 to 10.71) | 0.35 | |
| Non-elevated hs-CRP levels with MAIs | 113 | 2 (1.8) | 0.81 (0.13 to 4.83) | 0.81 | 1.38 (0.18 to 10.52) | 0.76 | |
| Elevated hs-CRP levels with NAI | 54 | 0 (0) | 0 (0) | 0.99 | 0 (0) | 0.99 | |
| Elevated hs-CRP levels with SAI | 141 | 4 (2.8) | 1.23 (0.27 to 5.53) | 0.79 | 2.38 (0.40 to 14.37) | 0.34 | |
| Elevated hs-CRP levels with MAIs | 84 | 2 (2.4) | 1.01 (0.17 to 6.10) | 0.99 | 2.24 (0.30 to 16.73) | 0.43 | |
*Model 1: adjusted for age and sex.
†Model 2: adjusted for age, sex, history of ischaemic stroke, TIA, myocardial infarction, known atrial fibrillation or flutter, angina, valvular heart disease, hypertension, diabetes mellitus and hypercholesterolaemia, smoking status, time to randomisation, NIHSS on admission, ICAS, qualifying events, treatment classification, antihypertensive medications, antidiabetic medications and lipid-lowering medications.
‡Composite events: stroke, myocardial infarction or death from cardiovascular causes.
Hs-CRP, high-sensitive C-reactive protein; ICAS, intracranial arterial stenosis; MAIs, multiple acute infarctions; NAI, no acute infarction; NIHSS, NIH Stroke Scale; SAI, single acute infarction; TIA, transient ischaemic attack.